Esperion Therapeutics Inc Announces Study 1002-058 Phase 2 Top-Line Results Conference Call Transcript
Good day, ladies and gentlemen, and welcome to the Esperion Study 058 Top-Line Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference over to Alex Schwartz, Senior Director of Investor Relations. Sir, you may begin.
Thank you. Good morning, ladies and gentlemen, and welcome. I'm Alex Schwartz, Head of Investor Relations here at Esperion. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. With us today from Esperion are Tim Mayleben, President and Chief Executive Officer; Bill Sasiela, Senior Vice President, Clinical Development; and Mark Glickman, Chief Commercial Officer.
I'd like to remind callers that information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |